ATE347374T1 - Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen - Google Patents

Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen

Info

Publication number
ATE347374T1
ATE347374T1 AT02706015T AT02706015T ATE347374T1 AT E347374 T1 ATE347374 T1 AT E347374T1 AT 02706015 T AT02706015 T AT 02706015T AT 02706015 T AT02706015 T AT 02706015T AT E347374 T1 ATE347374 T1 AT E347374T1
Authority
AT
Austria
Prior art keywords
immunization
compositions
methods
pseudomonas antigen
antigen
Prior art date
Application number
AT02706015T
Other languages
English (en)
Inventor
Dara W Frank
Jeannine Wiener-Kronish
Timothy L Yahr
Teiji Sawa
Robert B Fritz
Original Assignee
Mcw Res Found Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/770,916 external-priority patent/US6827935B2/en
Application filed by Mcw Res Found Inc, Univ California filed Critical Mcw Res Found Inc
Application granted granted Critical
Publication of ATE347374T1 publication Critical patent/ATE347374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
AT02706015T 2001-01-26 2002-01-25 Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen ATE347374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/770,916 US6827935B2 (en) 1998-11-25 2001-01-26 Method of and compositions for immunization with the pseudomonas V antigen
US26479501P 2001-01-29 2001-01-29

Publications (1)

Publication Number Publication Date
ATE347374T1 true ATE347374T1 (de) 2006-12-15

Family

ID=26950766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02706015T ATE347374T1 (de) 2001-01-26 2002-01-25 Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen

Country Status (8)

Country Link
US (2) US7494653B2 (de)
EP (1) EP1353688B1 (de)
JP (1) JP4355786B2 (de)
AT (1) ATE347374T1 (de)
DE (1) DE60216564T2 (de)
DK (1) DK1353688T3 (de)
ES (1) ES2275840T3 (de)
WO (1) WO2002064161A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7075502B1 (en) 1998-04-10 2006-07-11 E Ink Corporation Full color reflective display with multichromatic sub-pixels
EP1790659B1 (de) * 2001-11-13 2013-07-31 ID Biomedical Corporation Pseudomonas aeruginosa Polypeptide
CA2466474C (en) * 2001-11-13 2012-10-09 Shire Biochem Inc. Compositions comprising spa-1, spa-2 and spa-3, polypeptides and related uses
AU2003248233A1 (en) 2003-08-01 2005-02-15 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences A method of preparing epitopes chimeric gene vaccine
CA2571673A1 (en) * 2004-06-28 2006-01-05 Proteome Systems Intellectual Property Pty Ltd Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
PL2248826T3 (pl) * 2008-01-10 2013-11-29 Shionogi & Co Przeciwciało skierowane przeciwko PcrV
CA2751433A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2010104052A1 (ja) * 2009-03-11 2010-09-16 塩野義製薬株式会社 抗緑膿菌作用を有するヒト化ＰｃｒＶ抗体
KR102225290B1 (ko) 2009-05-02 2021-03-09 가부시키가이샤 한도오따이 에네루기 켄큐쇼 표시 장치 및 전자 기기
WO2010128614A1 (en) 2009-05-02 2010-11-11 Semiconductor Energy Laboratory Co., Ltd. Display device
SMT202000542T1 (it) 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
EP2820043B1 (de) * 2012-03-02 2020-01-15 Ablynx N.V. Biparatopische pseudomonas aeruginoas pcrv bindende variable einzeldomänen antikörper
ES2967001T3 (es) 2017-06-23 2024-04-25 Affinivax Inc Composiciones inmunogénicas
JP2020534859A (ja) 2017-09-29 2020-12-03 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 緑膿菌による肺定着／感染の発現リスクを予測する方法
AU2020292283A1 (en) 2019-06-11 2021-12-23 Regeneron Pharmaceuticals, Inc. Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
WO2021004446A1 (en) 2019-07-09 2021-01-14 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2025003381A1 (en) 2023-06-28 2025-01-02 Universität Zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599665A (en) 1993-12-21 1997-02-04 Mcw Research Foundation Pseudomonas aeruginosa nucleic acids encoding exoenzyme S activity and use thereof in detecting pseudomonas aeruginosa infection
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ES2255329T3 (es) 1998-11-25 2006-06-16 Mcw Research Foundation, Inc. Metodo y composiciones para inmunizacion con el antigeno v de pseudomonas aeruginosa.

Also Published As

Publication number Publication date
JP4355786B2 (ja) 2009-11-04
WO2002064161A3 (en) 2002-12-12
DK1353688T3 (da) 2007-04-10
WO2002064161A9 (en) 2002-10-31
JP2005500250A (ja) 2005-01-06
WO2002064161A2 (en) 2002-08-22
US7494653B2 (en) 2009-02-24
DE60216564D1 (de) 2007-01-18
US20090191241A1 (en) 2009-07-30
DE60216564T2 (de) 2007-10-11
US20050063985A1 (en) 2005-03-24
US8101347B2 (en) 2012-01-24
EP1353688B1 (de) 2006-12-06
ES2275840T3 (es) 2007-06-16
EP1353688A2 (de) 2003-10-22

Similar Documents

Publication Publication Date Title
ATE347374T1 (de) Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen
DE69930166D1 (de) Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
SE0001275L (sv) Öronpropp
DE60202877D1 (de) Gezieltes antikörper-verfahren
EP1285271A4 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens(04.12.03)
NO20014491D0 (no) Fremgangsmåte
FR12C0004I1 (de)
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
DE69930503D1 (de) Bedeckter siliziumfilm und verfahren zu dessen herstellung
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
HUP0303655A2 (hu) Proliferatív ileitis elleni hatékonyabb vakcinák, előállításuk és alkalmazásuk
PT946873E (pt) Metodos para diagnostico da aspergilose broncopulmonar alergica
IL162182A (en) Kits containing oral contraceptives and methods utilizing the same
DK0749582T3 (da) Fremgangsmåde til diagnosticering af præeklampsi
ATE234466T1 (de) Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten
DE60232244D1 (de) Nachweis und behandlung von prostatakrebs
ES2068599T3 (es) Procedimiento de reduccion de interferencias en un dosificado por fluorescencia.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
WO2003084384A3 (en) Diagnosis of flavivirus infection
NO963497L (no) Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE210460T1 (de) Zusammensetzungen, welche adp-ribosyltransferase- aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1353688

Country of ref document: EP